Bortezomib is a so-called proteasome inhibitor believed to play a crucial role in controlling cell function as well as growth. In order to interfere with their function, bortezomib can destroy cancer cells. is used for the treatment of multiple myeloma (a cancer of the bone marrow) in patients aged older than 18 years.
Regular blood tests should be performed prior to and while on treatment with bortezomib, to check the blood cell counts on a regular basis.